NCT00310076View on ClinicalTrials.gov

Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2012

Conditions
Carcinoma of the AppendixColorectal Cancer
Interventions
DRUG

thalidomide

Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.

PROCEDURE

surgery

Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy

Trial Locations (1)

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT00310076 - Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer | Biotech Hunter | Biotech Hunter